Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

NRAS Q61K

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	AZD5363 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) AZD5363 Sensitive : D AACR 2023 - 2wk	AZD5363 Sensitive: D – Preclinical AACR 2023 - 2 weeks AZD5363 Sensitive : D AACR 2023 - 2 weeks - (New D)
NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	trametinib + dabrafenib Resistant: C3 – Early Trials trametinib + dabrafenib Resistant : C3	trametinib + dabrafenib Resistant: C3 – Early Trials trametinib + dabrafenib Resistant : C3
NRAS Q61K	Hepatocellular Cancer	NRAS Q61K	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3
NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS Q61K	Thyroid Gland Carcinoma	NRAS Q61K	Thyroid Gland Carcinoma	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
NRAS Q61K	Non Small Cell Lung Cancer	NRAS Q61K	Non Small Cell Lung Cancer	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3
NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D
NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	trametinib + palbociclib Resistant: D – Preclinical trametinib + palbociclib Resistant : D	trametinib + palbociclib Resistant: D – Preclinical trametinib + palbociclib Resistant : D
NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	selumetinib Sensitive: D – Preclinical selumetinib Sensitive : D	selumetinib Sensitive: D – Preclinical selumetinib Sensitive : D
NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	trametinib Resistant: D – Preclinical trametinib Resistant : D	trametinib Resistant: D – Preclinical trametinib Resistant : D
NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	SBI-756 Sensitive: D – Preclinical SBI-756 Sensitive : D	SBI-756 Sensitive: D – Preclinical SBI-756 Sensitive : D
NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	dabrafenib Resistant: D – Preclinical dabrafenib Resistant : D	dabrafenib Resistant: D – Preclinical dabrafenib Resistant : D
NRAS Q61K	Neuroblastoma	NRAS Q61K	Neuroblastoma	ASN007 Sensitive: D – Preclinical ASN007 Sensitive : D	ASN007 Sensitive: D – Preclinical ASN007 Sensitive : D